Company Information

MMQCI designs and markets molecular quality control products for use in inherited disease testing, infectious disease detection, and monitoring of oncology treatment.

MMQCI will design and produce quality controls as needed for emerging nucleic acid technologies as they come into use by the molecular diagnostic community. Maine Molecular Quality Controls, Inc. was founded to provide the biomedical industry with innovative, high-quality control products for molecular diagnostic tests.

The company was formed in January 2000 by the two principals, Joan Gordon and Clark Rundell, Ph.D. Both founders of MMQCI have a strong background in clinical laboratory testing, as well as extensive research and development skills in the molecular biology field. As long-term workers in a clinical laboratory at Maine's largest healthcare facility, they are thoroughly familiar with the importance of controls in assuring laboratory accuracy, as well as the Federal regulations governing their use. While implementing novel genetic testing assays in the newly established Maine Medical Center Molecular Pathology Laboratory, Dr. Rundell invented and patented a process to stabilize target DNA constructs for utilization as controls in molecular-based diagnostic assays. Ms. Gordon, President of MMQCI, developed protocols based on this patented process to manufacture an FDA-cleared quality control for an infectious disease test platform. Dr. Rundell and Ms. Gordon subsequently founded MMQCI to pursue further research and development of technologies needed for other molecular control products. Funds from the National Institutes of Health (NIH) and Maine Technology Institute (MTI) have assisted the development of new technologies used in MMQCI products.

 

MMQCI     10 Southgate Road, Suite 170,  Scarborough, ME 04074      207.885.1072      Fax  207.885.1079